account_id none on file
legal_name Anebulo Pharmaceuticals, Inc.
ticker ANEB
cik 1815974
domain anebulo.com
linkedin_company_url https://www.linkedin.com/company/anebulo-pharmaceuticals
entry_point_account_id none on file
name Anebulo Pharmaceuticals Inc.
exchange OTC
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 8 executives 1 family 0
why_nownone on file
callsnone on file
filings
associated with research and development activities of consultants, including travel expense; ● other third-party expenses directly attributable to the development of our product candidates; and ● amortization expense for future asset purchases used in research and development activities.
filing / Feb 12, 2026 / receipt
Office Lease, Manufacturing Contract and CRO Contract We manage our business operations from our principal executive office in Lakeway, Texas, in leased space under a sublease with a related party for approximately $400 per month.
filing / Feb 12, 2026 / receipt
associated with research and development activities of consultants, including travel expense; ● other third-party expenses directly attributable to the development of our product candidates; and ● amortization expense for asset purchases used in research and development activities.
filing / Sep 29, 2025 / receipt
George was appointed as our part time Chief Financial Officer on September 28, 2023. Pursuant to his offer letter, we compensated
filing / Sep 29, 2025 / receipt
Such cost containment programs include restrictions on coverage and reimbursement, price controls and requirements to substitute branded prescription drugs with generic products.
filing / Sep 29, 2025 / receipt
We believe our present office space is adequate for our current operations and for near-term planned expansion. We recorded rent expense of approximately $4,800 for the fiscal years ended June 30, 2025 and 2024.
filing / Sep 29, 2025 / receipt
Office Lease, Manufacturing Contract and CRO Contract We manage our business operations from our principal executive office in Lakeway, Texas, in leased space under a sublease with a related party for approximately $400 per month.
filing / Sep 29, 2025 / receipt
appointed Richard Anthony Cunningham (55), the Company’s current Chief Executive Officer , to serve as the Company’s Interim Chief Financial Officer, Interim Principal Financial Officer and Interim Principal Accounting Officer, effective as of P1D September 30, 2025.
filing / Sep 29, 2025 / receipt
executives
| Richard (Richie) Anthony Cunningham | Chief Executive Officer | - | receipt |
familynone on file
upcomingnone on file
changes
| 2023-10-06 | Chief Executive Officer, appointed | sec_8k |
| 2023-09-05 | Acting Chief Financial Officer, departed | sec_8k |
| 2023-03-08 | Acting Chief Financial Officer, appointed | sec_8k |
mcp_package_hint
slug anebulo-pharmaceuticals-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$